Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over losses of $(12.91) per
Hemab lost more money per share than experts thought it would—it lost 80 cents instead of the predicted 52 cents. When a company loses more money than people expected, it can make investors worried about whether the company is on the right track.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.